BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

最近更新时间: 04 Aug, 2:54AM

44.23

0.92 (2.12%)

  • 1天 2.12%
  • 5天 -6.88%
  • 1月 -8.69%
  • 6月 -26.27%
  • 今年至今天 -22.12%
  • 1年 -11.52%
  • 5年 -25.70%
前收盘价格 43.31
收盘价格 43.61
成交量 15,956,266
平均成交量 (3个月) 14,423,022
市值 90,027,507,712
市盈率 (P/E TTM) 17.76
预期市盈率 (P/E Forward) 7.82
价格/销量 (P/S) 2.01
股市价格/股市净资产 (P/B) 5.50
52周波幅
42.96 (-2%) — 63.33 (43%)
利润日期 30 Oct 2025
股息率 (DY TTM) 2.76%
营业毛利率 11.38%
营业利益率 (TTM) 31.57%
稀释每股收益 (EPS TTM) 2.68
季度收入增长率 (YOY) -5.60%
季度盈利增长率 (YOY) -95.90%
总债务/股东权益 (D/E MRQ) 293.85%
流动比率 (MRQ) 1.28
营业现金流 (OCF TTM) 14.31 B
杠杆自由现金流 (LFCF TTM) 13.93 B
资产报酬率 (ROA TTM) 7.24%
股东权益报酬率 (ROE TTM) 31.99%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看跌
Drug Manufacturers - General (全球的) 混合的 看跌
股票 Bristol-Myers Squibb Company 看跌 看跌

AIStockmoo 评分

-1.2
分析师共识 -4.5
内部交易活动 -2.5
价格波动 0.5
技术平均移动指标 0.0
技术振荡指标 0.5
平均 -1.20

相关股票

股票 市值 DY P/E（TTM） P/B
BMY 90 B 2.76% 17.76 5.50
JNJ 428 B 1.40% 18.99 5.48
ABBV 386 B 2.21% 103.97 50.46
PFE 135 B 3.58% 12.58 1.53
GSK 78 B 2.03% 18.27 4.18
LLY 677 B 0.37% 49.28 37.06

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.07%
机构持股比例 82.11%
52周波幅
42.96 (-2%) — 63.33 (43%)
目标价格波幅
34.00 (-23%) — 47.00 (6%)
高 47.00 (Citigroup, 6.26%) 保留
中 40.50 (-8.43%)
低 34.00 (Morgan Stanley, -23.13%) 卖出
平均值 40.50 (-8.43%)
总计 1 保留, 1 卖出
平均价格@调整类型 46.38
公司 日期 目标价格 调整类型 价格@调整类型
Citigroup 01 Aug 2025 47.00 (6.26%) 保留 44.23
Morgan Stanley 10 Jul 2025 34.00 (-23.13%) 卖出 48.52
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
ELKINS DAVID V - 47.41 -56,000 -2,654,960
SHORT BARTIE WENDY - 47.18 -632 -29,818
累积净数量 -56,632
累积净值 ($) -2,684,778
累积平均购买 ($) -
累积平均卖出 ($) 47.30
名称 持有人 日期 类型 数量 价格 价值 ($)
ELKINS DAVID V 职员 02 Sep 2025 自动卖出 (-) 56,000 47.41 2,654,960
SHORT BARTIE WENDY 职员 01 Sep 2025 处理 (-) 632 47.18 29,818
SHORT BARTIE WENDY 职员 01 Sep 2025 执行期权 1,235 - -
  • 3M
日期 类型 细节
29 Aug 2025 公告 Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
29 Aug 2025 公告 Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
25 Aug 2025 公告 Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
18 Aug 2025 公告 Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04 Aug 2025 公告 Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
04 Aug 2025 公告 Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
31 Jul 2025 CNBC Pandemic darlings Moderna, BioNTech are now on two different paths
31 Jul 2025 公告 Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
28 Jul 2025 公告 Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
25 Jul 2025 公告 Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
21 Jul 2025 公告 Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
18 Jul 2025 公告 Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
17 Jul 2025 公告 Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
17 Jul 2025 CNBC Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
26 Jun 2025 公告 U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
17 Jun 2025 公告 Bristol Myers Squibb Announces Dividend
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
16 Jun 2025 公告 Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
显示更多
股息率 (DY TTM) 2.76%
5年平均股息收益率 3.55%
股息支付比率 91.04%
预计下次股息支付 Nov 2025
除息日 公告日期 支付日期 详情
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 现金
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 现金
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 现金
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 现金
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 现金
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 现金
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 现金
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 现金
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 现金
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 现金
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 现金
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 现金
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 现金
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 现金
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 现金
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 现金
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 现金
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 现金
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 现金
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 现金
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 现金
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 现金
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 现金
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 现金
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 现金
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 现金
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 现金
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 现金
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 现金
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 现金
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 现金
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 现金
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 现金
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 现金
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 现金
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 现金
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 现金
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 现金
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 现金
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 现金
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 现金
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 现金
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 现金
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 现金
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 现金
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 现金
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 0.620 1 1.40
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票